| http://www.w3.org/ns/prov#value | - According to another preferred embodiment blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR. According to another preferred embodiment at least one FcR-modulating substance minimising production of interleukin-1 receptor antagonist
|
